60 Degrees Pharmaceuticals Inc (SXTP)

$1.46 +0.01 (0.69%)
Market Cap 3.86M
Revenue (ttm) 1.41M
Net Income (ttm) -7.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -522.70%
Debt to Equity Ratio 0.00
Volume 32,500
Avg Vol 99,184
Day's Range N/A - N/A
Shares Out 2.66M
Stochastic %K 8%
Beta 2.47
Analysts Sell
Price Target $3.70

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumoni...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 327 5422
Address:
1025 Connecticut Avenue NW, Suite 1000, Washington, United States
prismmarketview
prismmarketview Jul. 9 at 1:04 PM
$SXTP adds more pipeline optionality. New exclusive option with Florida State University Research Foundation gives them first crack at castanospermine for Powassan, TBE, alpha-gal and post-treatment Lyme. Nice fit with their vector-borne niche. #SXTP #Biotech #SmallCaps #TickBorneDisease https://prismmarketview.com/60-degrees-pharmaceuticals-secures-new-castanospermine-opportunity-in-tick-borne-disease/
0 · Reply
BULLETSTOCK
BULLETSTOCK Jul. 8 at 12:43 PM
$IOTR or $SXTP You Choose 🚀 $SXTP 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
1 · Reply
STACKD0E
STACKD0E Jul. 8 at 12:15 PM
$NCRA $HSTA $URGN $SXTP $LNTO ✨️
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 8 at 12:02 PM
$SXTP 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
1 · Reply
DollarRollers
DollarRollers Jul. 2 at 10:09 AM
$SXTP nice news out now
1 · Reply
Merlintrader
Merlintrader Jul. 1 at 1:19 PM
$MODD Biotech Radar July 1, 2026: $CANF, ,$SXTP and Lead Today’s Catalyst Watchhttps://www.merlintrader.com/biotech-radar-july1/
0 · Reply
focafoca99
focafoca99 Jul. 1 at 12:19 PM
$SXTP noted DSMB recommendation to continue B-Free Phase 2 study of tafenoquine for chronic babesiosis.
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 1 at 12:02 PM
$SXTP 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jun. 28 at 6:25 PM
Small-Caps with Catalysts this week: 👇👇 ( $PHIO, $SXTP, $PSEC, $IBO, $LHAI, etc...) #NASDAQ #NYSE
0 · Reply
topstockalerts
topstockalerts Jun. 17 at 6:15 PM
$SXTP that was a sharp rejection of lower prices.
0 · Reply
Latest News on SXTP
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

Jul 8, 2026, 8:01 AM EDT - 6 days ago

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

60 Degrees Pharmaceuticals Proxy statement: Proxy filing

Jul 2, 2026, 8:00 AM EDT - 12 days ago

60 Degrees Pharmaceuticals Proxy statement: Proxy filing

60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study

2026-07-01T12:25:16.000Z - 13 days ago

60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Jul 1, 2026, 8:02 AM EDT - 13 days ago

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

60 Degrees executes patent licensing agreement with Florida State

2026-06-11T13:01:09.000Z - 4 weeks ago

60 Degrees executes patent licensing agreement with Florida State

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

Jun 11, 2026, 8:03 AM EDT - 4 weeks ago

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharmaceuticals Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

60 Degrees Pharmaceuticals Proxy statement: Proxy filing

60 Degrees announces early enrollment of first patient in trial of tafenoquine

2026-05-26T14:57:43.000Z - 7 weeks ago

60 Degrees announces early enrollment of first patient in trial of tafenoquine

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

May 26, 2026, 8:02 AM EDT - 7 weeks ago

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending

2026-05-20T16:00:11.000Z - 7 weeks ago

H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending

60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

2026-05-20T15:55:36.000Z - 7 weeks ago

60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

May 15, 2026, 8:42 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

60 Degrees Pharmaceuticals Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Quarterly report: Q1 2026

60 Degrees Pharmaceuticals Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Earnings release: Q1 2026

60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 10:00 AM EDT - 3 months ago

60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website

2026-04-15T12:37:07.000Z - 3 months ago

60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website

60 Degrees Pharmaceuticals Announces 2025 Annual Results

Mar 31, 2026, 7:01 AM EDT - 3 months ago

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

60 Degrees Pharmaceuticals Annual report: Q4 2025

60 Degrees submits NDIN to FDA for Australian Chestnut Extract

2026-03-18T12:12:35.000Z - 4 months ago

60 Degrees submits NDIN to FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

Mar 18, 2026, 8:01 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees reports all patients cured of babesiosis after tafenoquine treatment

2026-03-11T11:30:55.000Z - 4 months ago

60 Degrees reports all patients cured of babesiosis after tafenoquine treatment

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

Mar 11, 2026, 7:24 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees expands access to Arakoda with GoodRx partnership

2026-02-02T13:21:06.000Z - 5 months ago

60 Degrees expands access to Arakoda with GoodRx partnership

GDRX

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Feb 2, 2026, 8:01 AM EST - 5 months ago

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split

2026-01-27T16:30:17.000Z - 6 months ago

60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split

Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today

2026-01-22T14:15:44.000Z - 6 months ago

Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today

60 Degrees Pharmaceuticals announces partnership with Runway Health

2026-01-22T13:27:13.000Z - 6 months ago

60 Degrees Pharmaceuticals announces partnership with Runway Health

60 Degrees Pharmaceuticals Inc trading halted, news pending

2026-01-17T00:50:18.000Z - 6 months ago

60 Degrees Pharmaceuticals Inc trading halted, news pending

60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split

2026-01-15T13:21:52.000Z - 6 months ago

60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Jan 15, 2026, 8:01 AM EST - 6 months ago

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

60 Degrees announces detection of babesia infection in 24% of patients in study

2025-12-29T13:10:58.000Z - 7 months ago

60 Degrees announces detection of babesia infection in 24% of patients in study

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Dec 29, 2025, 8:01 AM EST - 7 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

60 Degrees Pharmaceuticals expanding Arakoda sales and marketing in 2026

2025-12-11T13:15:24.000Z - 7 months ago

60 Degrees Pharmaceuticals expanding Arakoda sales and marketing in 2026

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Dec 11, 2025, 8:01 AM EST - 7 months ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Nov 21, 2025, 8:01 AM EST - 8 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

60 Degrees Pharmaceuticals Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

60 Degrees Pharmaceuticals Earnings release: Q3 2025

60 Degrees Pharmaceuticals Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

60 Degrees Pharmaceuticals Quarterly report: Q3 2025

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Nov 13, 2025, 1:51 PM EST - 8 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

60 Degrees Pharmaceuticals Transcript: Investor Update

Oct 22, 2025, 4:15 PM EDT - 9 months ago

60 Degrees Pharmaceuticals Transcript: Investor Update

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Oct 15, 2025, 7:14 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Oct 9, 2025, 7:04 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 3:30 PM EDT - 11 months ago

60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:02 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Sep 2, 2025, 8:00 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Aug 27, 2025, 8:00 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT - 11 months ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 19, 2025, 8:54 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Aug 13, 2025, 4:14 PM EDT - 11 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Earnings release: Q2 2025

60 Degrees Pharmaceuticals Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Quarterly report: Q2 2025

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 16, 2025, 4:01 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 15, 2025, 7:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Jul 7, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 4, 2025, 8:56 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Jun 3, 2025, 8:49 AM EDT - 1 year ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 4:31 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

60 Degrees Pharmaceuticals Quarterly report: Q1 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Quarterly report: Q1 2025

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 22, 2025, 8:44 AM EDT - 1 year ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 10, 2025, 8:31 AM EDT - 1 year ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Apr 8, 2025, 8:31 AM EDT - 1 year ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals Earnings release: Q4 2024

Mar 27, 2025, 2:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Earnings release: Q4 2024

60 Degrees Pharmaceuticals Annual report: Q4 2024

Mar 27, 2025, 2:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Annual report: Q4 2024

60 Degrees Pharmaceuticals Slides: Q4 2024

Mar 27, 2025, 2:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Slides: Q4 2024

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 21, 2025, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 20, 2025, 10:36 AM EST - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Feb 14, 2025, 7:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 11, 2025, 12:59 PM EST - 1 year ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 6, 2025, 2:07 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 1 year ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 28, 2025, 8:01 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Jan 8, 2025, 8:02 AM EST - 1 year ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 23, 2024, 8:57 AM EST - 1 year ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 11, 2024, 8:56 AM EST - 1 year ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Dec 2, 2024, 4:05 PM EST - 1 year ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 14, 2024, 2:31 PM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 12:30 PM EST - 1 year ago

60 Degrees Pharmaceuticals Quarterly report: Q3 2024

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 3, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Oct 2, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Sep 19, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 4, 2024, 8:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 28, 2024, 2:48 PM EDT - 2 years ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 11:01 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Quarterly report: Q2 2024

60 Degrees Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Earnings release: Q2 2024

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 12, 2024, 9:12 AM EDT - 2 years ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Aug 6, 2024, 9:26 AM EDT - 2 years ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 25, 2024, 9:02 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 19, 2024, 8:29 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

prismmarketview
prismmarketview Jul. 9 at 1:04 PM
$SXTP adds more pipeline optionality. New exclusive option with Florida State University Research Foundation gives them first crack at castanospermine for Powassan, TBE, alpha-gal and post-treatment Lyme. Nice fit with their vector-borne niche. #SXTP #Biotech #SmallCaps #TickBorneDisease https://prismmarketview.com/60-degrees-pharmaceuticals-secures-new-castanospermine-opportunity-in-tick-borne-disease/
0 · Reply
BULLETSTOCK
BULLETSTOCK Jul. 8 at 12:43 PM
$IOTR or $SXTP You Choose 🚀 $SXTP 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
1 · Reply
STACKD0E
STACKD0E Jul. 8 at 12:15 PM
$NCRA $HSTA $URGN $SXTP $LNTO ✨️
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 8 at 12:02 PM
$SXTP 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
1 · Reply
DollarRollers
DollarRollers Jul. 2 at 10:09 AM
$SXTP nice news out now
1 · Reply
Merlintrader
Merlintrader Jul. 1 at 1:19 PM
$MODD Biotech Radar July 1, 2026: $CANF, ,$SXTP and Lead Today’s Catalyst Watchhttps://www.merlintrader.com/biotech-radar-july1/
0 · Reply
focafoca99
focafoca99 Jul. 1 at 12:19 PM
$SXTP noted DSMB recommendation to continue B-Free Phase 2 study of tafenoquine for chronic babesiosis.
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 1 at 12:02 PM
$SXTP 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jun. 28 at 6:25 PM
Small-Caps with Catalysts this week: 👇👇 ( $PHIO, $SXTP, $PSEC, $IBO, $LHAI, etc...) #NASDAQ #NYSE
0 · Reply
topstockalerts
topstockalerts Jun. 17 at 6:15 PM
$SXTP that was a sharp rejection of lower prices.
0 · Reply
Goatcheese
Goatcheese Jun. 17 at 5:41 PM
$SXTP what’s the news
1 · Reply
Fringe
Fringe Jun. 17 at 4:21 PM
$SXTP nice scalp Run already over That was fast.
0 · Reply
uptrend2025
uptrend2025 Jun. 17 at 4:20 PM
$SXTP Wow nice move!
0 · Reply
Technicalcharter
Technicalcharter Jun. 17 at 4:00 PM
$SXTP remember this when you see this moving
1 · Reply
DipBuyInvester
DipBuyInvester Jun. 17 at 3:49 PM
$SXTP Told you!! Patience is the key. $HITI is next.
2 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jun. 15 at 10:55 PM
$SXTP CEO purchased 7,350 shares at $1.38 for a total of $10,131. DOW GEOFFREY S now owns 24,131 shares. https://ceo-buys.com
0 · Reply
Technicalcharter
Technicalcharter Jun. 15 at 8:34 PM
$SXTP double bottom is tested and now 1.87 then 2.39 incoming
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 15 at 4:06 PM
$SXTP Will turn into 90 degrees from 60 degrees. Stay tuned.
1 · Reply
DipBuyInvester
DipBuyInvester Jun. 15 at 12:33 PM
$SXTP Moving up as expected. Load the boat.
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 15 at 8:24 AM
$SXTP 60 degrees turning into 90 degrees. Load the boat.
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 12 at 10:14 PM
$SXTP Hold for gold. Patience is the key!!Anytime 2X potential.
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 12 at 11:09 AM
$SXTP will send it to next level.
0 · Reply